We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Revance Therapeutics Inc | NASDAQ:RVNC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.2492 | 6.61% | 4.0192 | 1.33 | 4.02 | 4.07 | 3.88 | 3.92 | 1,533,475 | 05:00:07 |
|
|
|
|
|
DELAWARE
|
|
001-36297
|
|
75-0551645
|
(State of
incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
ITEM 5.02.
|
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
|
Name
|
|
2017 Cash Bonus
|
|
2018 Base Salary
|
|
2018 Target Bonus Percentage
|
|||||
L. Daniel Browne
President and Chief Executive Officer
|
|
$
|
466,038
|
|
|
$
|
565,000
|
|
|
66
|
%
|
Lauren P. Silvernail
Chief Financial Officer and Chief Business Officer
|
|
$
|
264,166
|
|
|
$
|
458,402
|
|
|
45
|
%
|
Abhay Joshi, Ph.D.
Chief Operating Officer
|
|
$
|
344,728
|
|
|
$
|
469,062
|
|
|
45
|
%
|
Name
|
|
Stock Options
|
|
Restricted Stock
|
||
L. Daniel Browne
President and Chief Executive Officer
|
|
169,000
|
|
|
28,250
|
|
Lauren P. Silvernail
Chief Financial Officer and Chief Business Officer
|
|
48,750
|
|
|
8,125
|
|
Abhay Joshi, Ph.D.
Chief Operating Officer
|
|
70,500
|
|
|
11,750
|
|
Date: February 9, 2018
|
Revance Therapeutics, Inc.
|
|
|
|
|
|
By:
|
/s/ Lauren P. Silvernail
|
|
|
Lauren P. Silvernail
|
|
|
Chief Financial Officer and Chief Business Officer
|
1 Year Revance Therapeutics Chart |
1 Month Revance Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions